Nami Therapeutics Corp (’Nami’) is a startup company based in Storrs, CT and currently participating in the Technology Incubation Program at the University of Connecticut. Nami is developing specifically designed nanoparticles for the targeted delivery of therapeutic agents, including radio-therapeutics, to tumors. Nami is using technologies licensed from the University of Connecticut and the University of North Carolina. The mission of Nami is to provide early, recurrent and late-stage cancer patients another chance for a cancer-free life. The current focus is to treat advanced ovarian cancer using tumor-specific delivery of radioisotope loaded nanoparticles. Nami is translating its nanotechnology-based products to the clinical trial stage by demonstrating their efficacy in preclinical models, and by completing IND enabling activities such as manufacturing process development (CMC) and safety/toxicity assessments.
OUR TEAM
-
Xiuling Lu, Ph.D. CEO
Over 18 years of experience working on drug formulations, in particular advancing nanotechnologies for cancer therapy
-
Michael Jay, Ph.D. Chief Scientific Officer
Former director of an FDA-registered cGMP manufacturing facility, Professor at the University of North Carolina at Chapel Hill
-
Ruobing Xia, MBA President (Business)
Over 20 years of experience in big pharma,managed hundred million dollar product launches and promotions
-
David Worthen Ph.D., J.D. Head of R&D
Senior scientist, project manager, group leader, and academic investigator in pharmaceuticals, polymers, veterinary
-
Ron Pion M.D. Clinical Advisor
Clinical Professor at the UCLA School of Medicine and a Fellow of the American College of Obstetricians and Gynecologists
-
Andrew Salner, M.D. Clinical Advisor
Medical Director，Hartford HealthCare Cancer Institute at Hartford Hospital.
-
Jeffrey C. Miller, MBA Business Advisor
Partner at KASTx Ventures, Co-Founder of TSP Therapeutics, leads a private biotechnology consulting practice, and is a former member of the board of directors at BIOTE Canada.